QQ客服 官方微博 反馈留言

	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu
	Senan, Suresh; Brade, Anthony M.; Wang, Luhua; Vansteenkiste, Johan F.; Dakhil, Shaker R.; Biesma, Bonne; Aguillo, Maite Martinez; Aerts, Joachim; Govindan, Ramaswamy; Rubio-Viqueira, Belen
	2015
卷号	33期号:15
ISSN号	0732-183X
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6386372
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Senan, Suresh,Brade, Anthony M.,Wang, Luhua,et al. Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu[J],2015,33(15).
APA	Senan, Suresh.,Brade, Anthony M..,Wang, Luhua.,Vansteenkiste, Johan F..,Dakhil, Shaker R..,...&Vokes, Everett E..(2015).Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu.,33(15).
MLA	Senan, Suresh,et al."Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu".33.15(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。